Home  »  Finance   »  Takeda Pharmaceutical Company Limited (NYSE: TAK)&...

Takeda Pharmaceutical Company Limited (NYSE: TAK)’s Loss Of -0.37% Profited Investors

Takeda Pharmaceutical Company Limited (NYSE:TAK) traded at $16.13 at close of the session on Tuesday, 01/24/23, made a downward move of -0.37% on its previous day’s price.

Looking at the stock we see that its previous close was $16.19 and the beta (5Y monthly) reads 0.75 with the day’s price range being $16.03 – $16.15. The company has a trailing 12-month PE ratio of 30.26. In terms of its 52-week price range, TAK has a high of $16.30 and a low of $12.28. The company’s stock has gained about 4.74% over that past 30 days.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Takeda Pharmaceutical Company Limited has a market cap of $50.51 billion. With its Forward Dividend at 1.06 and a yield of 6.55%, the company’s investors could be anxious for the TAK stock to gain ahead of the earnings release.

There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the TAK stock, short term indicators assign the stock an average of 100% Buy, while medium term indicators assign it an average of 100% Buy. Long term indicators on average place the stock in the category of 50% Buy.

Based on estimates by 14 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 7 have rated the Takeda Pharmaceutical Company Limited (TAK) stock as a Hold, while 5 rate it as a Buy. 1 analyst(s) rate it as overweight while 1 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Overweight and investors could take advantage and scoop up stock of the company.

Looking further, we note that the PEG ratio for the TAK stock currently stands at 378.28, and the current price level is 2.51% off its SMA20 and 7.44% from its 50-day simple moving average. The RSI (14) is pointing at 66.74 while the volatility over the past week is 1.08% and jumps to 1.14% over the past one month. The beta value is 0.68, while the average true range (ATR) is currently pointing at 0.21. The average price target for the stock over the next 12 months is $17.14, with the estimates having a low of $13.56 and a high of $25.52. These price ends are 15.93% and -58.21% off the current price level respectively, although investors could be excited at the prospect of a -1.18% if the TAK share price touches on the median price of $16.32.

Let’s briefly compare Takeda Pharmaceutical Company Limited (TAK) stock to its peers. We find that current price change of -0.37% and 10.03% over the past 12 months for TAK. Another of its peers Sanofi (SNY) has dropped -0.21% previous session, and was -4.78% down over the past year, while Pfizer Inc. (PFE) was also down -0.60% in the last session, while its price remained in the red at -15.31% over the same period. Takeda Pharmaceutical Company Limited has a P/E ratio of 30.26 compared to Johnson & Johnson’s 23.43 and Sanofi’s 17.62. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial were at -0.07% and 0.31%, respectively, at close of the trading.

Coming back to Takeda Pharmaceutical Company Limited (NYSE:TAK), we note that the average 3-month trading volume was 2.86 million, while that of the preceding 10-day period stands at 3.31 million. Current shares outstanding are 3.10 billion.

The institutions hold 2.10%. The data shows that short shares as of Oct 13, 2022, stood at 6.32 million at a short ratio of 2.05. This represents a 0.20% short interest in shares outstanding on Oct 13, 2022. Shares short rose in October from the previous month at 3.44 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock 3.40% up in year-to-date price movement.

Leave a Comment

Your email address will not be published. Required fields are marked *

5 Lithium Stocks with High Future Potential

Demand for lithium is expected to increase 8-fold by 2030. The world's largest automakers are racing to go green as the global EV boom continues.


We have collated a list of top five lithium stocks which are well positioned to benefit from the 2023 lithium boom because of their focus on multiple high-potential lithium projects.

100% free. stop anytime no spam